[go: up one dir, main page]

WO2006072792A3 - Composes se liant au site actif des proteines kinases - Google Patents

Composes se liant au site actif des proteines kinases Download PDF

Info

Publication number
WO2006072792A3
WO2006072792A3 PCT/GB2006/000034 GB2006000034W WO2006072792A3 WO 2006072792 A3 WO2006072792 A3 WO 2006072792A3 GB 2006000034 W GB2006000034 W GB 2006000034W WO 2006072792 A3 WO2006072792 A3 WO 2006072792A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
treatment
nerve cell
trauma
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/000034
Other languages
English (en)
Other versions
WO2006072792A2 (fr
Inventor
Veronique Birault
Clifford John Harris
Roger Crossley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of WO2006072792A2 publication Critical patent/WO2006072792A2/fr
Publication of WO2006072792A3 publication Critical patent/WO2006072792A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un ou plusieurs composés qui sont des inhibiteurs d'une sérine/thréonine kinase et, d'une manière plus spécifique, de la Rho kinase (ROK, ROCK). Ces composés peuvent être utilisé dans la fabrication d'un médicament pour le traitement ou la prévention d'une maladie choisie dans le groupe constitué : d'une affection oculaire telle que la dégénérescence maculaire liée à l'âge, une maladie de la glande lacrymale ou la rétinopathie diabétique ou la suppression du développement de neurites et donc à une affection nécessitant l'extension et la connectivité de cellules nerveuses, la régénération des neurones, l'induction du développement de nouveaux axones et la promotion du (re)câblage d'axones, la réparation de lésions des neurones dans le SNC provoquées par un traumatisme (par exemple un accident cérébrovasculaire, une lésion cérébrale traumatique, etc.) ou par une neurodégénérescence (par exemple la maladie d'Alzheimer, la maladie de Parkinson, etc.), à la réparation ou la récupération de troubles tels qu'une lésion de la moelle épinière et le traitement de ceux-ci et la réduction des effets subséquents de ceux-ci ou de la douleur provoquée par une lésion des cellules nerveuses telle que celle consécutive à un traumatisme ou à une amputation par exemple dans le traitement de la douleur neuropathique. Les composés selon l'invention sont choisis dans un groupe spécifique de composés qui comprend des composés représentés par la formule (I) ou (II), dans laquelle R1, R2, R3, R4, R5 et R6 sont tels que définis dans le descriptif.
PCT/GB2006/000034 2005-01-07 2006-01-06 Composes se liant au site actif des proteines kinases Ceased WO2006072792A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500226.6A GB0500226D0 (en) 2005-01-07 2005-01-07 Compounds which bind to the active site of protein kinase enzymes
GB0500226.6 2005-01-07

Publications (2)

Publication Number Publication Date
WO2006072792A2 WO2006072792A2 (fr) 2006-07-13
WO2006072792A3 true WO2006072792A3 (fr) 2007-01-11

Family

ID=34203716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/000034 Ceased WO2006072792A2 (fr) 2005-01-07 2006-01-06 Composes se liant au site actif des proteines kinases

Country Status (2)

Country Link
GB (1) GB0500226D0 (fr)
WO (1) WO2006072792A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
CN105985322A (zh) * 2015-03-03 2016-10-05 苏州翔实医药发展有限公司 氨基吡嗪化合物及其用途
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (fr) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Procédés et compositions pharmaceutiques pour le traitement de non-perfusion capillaire rétinienne
WO2025224050A1 (fr) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Méthodes de traitement de patients souffrant d'hypomélanose de ito

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087853A1 (fr) * 2000-05-17 2001-11-22 Universite Catholique De Louvain Derives de pyrazine et d'imidazopyrazine comme antioxydants
WO2002024681A2 (fr) * 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase
US20030103957A1 (en) * 2001-04-12 2003-06-05 Mckerracher Lisa Fusion proteins
WO2003062227A1 (fr) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Inhibiteurs de kinase rho
WO2004085409A2 (fr) * 2003-03-28 2004-10-07 Biofocus Discovery Ltd Bibliotheque de composes
WO2005003101A2 (fr) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Composes se liant au site actif d'enzymes proteine kinases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087853A1 (fr) * 2000-05-17 2001-11-22 Universite Catholique De Louvain Derives de pyrazine et d'imidazopyrazine comme antioxydants
WO2002024681A2 (fr) * 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase
US20030103957A1 (en) * 2001-04-12 2003-06-05 Mckerracher Lisa Fusion proteins
WO2003062227A1 (fr) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Inhibiteurs de kinase rho
WO2004085409A2 (fr) * 2003-03-28 2004-10-07 Biofocus Discovery Ltd Bibliotheque de composes
WO2005003101A2 (fr) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Composes se liant au site actif d'enzymes proteine kinases

Also Published As

Publication number Publication date
WO2006072792A2 (fr) 2006-07-13
GB0500226D0 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
WO2021178237A3 (fr) Compositions oligonucléotidiques et méthodes associées
WO2006071548A3 (fr) Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase
WO2009127642A3 (fr) Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
WO2007022506A3 (fr) Méthodes et préparations pour le traitement d'une maladie neurologique
EP1378247A4 (fr) Agents pour le traitement de maladies de la function visuelle
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
WO2007076360A8 (fr) (indazol-5-yl)-pyrazines et (1,3-dihydro-indol-2-un)- pyrazines pour le traitement de maladies et de conditions a mediation de rho kinase
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
WO2008157791A3 (fr) Procédés et compositions pour stimuler la neurogenèse et inhiber une dégénérescence neuronale à l'aide d'isothiazolopyrimidinones
WO2010028088A3 (fr) Composants à liaison soufre pour le traitement de maladies et de troubles ophtalmiques
CA2498291A1 (fr) Composes diazabicycliques utilises dans le traitement de troubles associes au snc
WO2006050045A3 (fr) Utilisation d'inhibiteurs de jun n-terminal kinases pour le traitement de la retinophatie glaucomateuse et de maladies oculaires
WO2010030936A3 (fr) Atg14l et rubicon : nouveaux régulateurs de l'autophagie
WO2006072792A3 (fr) Composes se liant au site actif des proteines kinases
WO2008048675A3 (fr) Traitement de la dégénération maculaire due au vieillissement et d'autres maladies oculaires
NO20064659L (no) Nye kvarterniserte quinuklidin-estere
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
NO20081845L (no) Imidazolforbindelser for behandling av neurologiske lidelser
WO2005016267A3 (fr) Composes d'oxazole destines au traitement de troubles neurodegenerescents
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
WO2007035722A8 (fr) Methodes et compositions permettant de stimuler la neurogenese et d'inhiber la degenerescence neuronale
WO2005095348A3 (fr) Composes pyrazole-amines utilises dans le traitement des troubles neurodegeneratifs
WO2005097114A3 (fr) Composes de thiazole sulfamide utiles pour le traitement des maladies neurodegeneratives
WO2003030836A3 (fr) Regeneration neuronale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06701082

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6701082

Country of ref document: EP